Hans J. Stauss
Monoclonal T-Cell Receptors: New Reagents for Cancer Therapy
Stauss, Hans J.; Cesco-Gaspere, Michela; Thomas, Sharyn; Hart, Daniel P.; Xue, Shao-An; Holler, Angelika; Wright, Graham; Perro, Mario; Little, Ann-Margaret; Pospori, Constantina; King, Judy; Morris, Emma C.
Authors
Michela Cesco-Gaspere
Sharyn Thomas
Daniel P. Hart
Shao-An Xue
Angelika Holler
Dr Graham Wright G.Wright2@napier.ac.uk
Associate Professor
Mario Perro
Ann-Margaret Little
Constantina Pospori
Judy King
Emma C. Morris
Abstract
Adoptive transfer of antigen-specific T lymphocytes is an effective form of immunotherapy for persistent virus infections and cancer. A major limitation of adoptive therapy is the inability to isolate antigen-specific T lymphocytes reproducibly. The demonstration that cloned T-cell receptor (TCR) genes can be used to produce T lymphocyte populations of desired specificity offers new opportunities for antigen-specific T-cell therapy. TCR gene-modified lymphocytes display antigen-specific function in vitro, and were shown to protect against virus infection and tumor growth in animal models. A recent trial in humans demonstrated that TCR gene-modified T cells persisted in all and reduced melanoma burden in 2/15 patients. In future trials, it may be possible to use TCR gene transfer to equip helper and cytotoxic T cells with new antigen-specificity, allowing both T-cell subsets to cooperate in achieving improved clinical responses. Sequence modifications of TCR genes are being explored to enhance TCR surface expression, while minimizing the risk of pairing between introduced and endogenous TCR chains. Current T-cell transduction protocols that trigger T-cell differentiation need to be modified to generate “undifferentiated” T cells, which, upon adoptive transfer, display improved in vivo expansion and survival. Both, expression of only the introduced TCR chains and the production of naïve T cells may be possible in the future by TCR gene transfer into stem cells.
Citation
Stauss, H. J., Cesco-Gaspere, M., Thomas, S., Hart, D. P., Xue, S.-A., Holler, A., Wright, G., Perro, M., Little, A.-M., Pospori, C., King, J., & Morris, E. C. (2007). Monoclonal T-Cell Receptors: New Reagents for Cancer Therapy. Molecular Therapy, 15(10), 1744-1750. https://doi.org/10.1038/sj.mt.6300216
Journal Article Type | Article |
---|---|
Acceptance Date | Apr 26, 2007 |
Online Publication Date | Jul 17, 2017 |
Publication Date | 2007-10 |
Deposit Date | May 4, 2020 |
Publicly Available Date | May 4, 2020 |
Journal | Molecular Therapy |
Print ISSN | 1525-0016 |
Publisher | Nature Publishing Group |
Peer Reviewed | Peer Reviewed |
Volume | 15 |
Issue | 10 |
Pages | 1744-1750 |
DOI | https://doi.org/10.1038/sj.mt.6300216 |
Keywords | Molecular Medicine; Genetics; Molecular Biology; Pharmacology; Drug Discovery |
Public URL | http://researchrepository.napier.ac.uk/Output/2658366 |
Files
Monoclonal T-Cell Receptors: New Reagents For Cancer Therapy
(840 Kb)
PDF
Publisher Licence URL
http://creativecommons.org/licenses/by-nc-nd/4.0/
Copyright Statement
Published under a Creative Commons Attribution NonCommercial NoDerivs (CC BY-NC-ND 4.0) license.
You might also like
Belonging to a learning community: staff perspectives.
(2018)
Presentation / Conference Contribution
MS TCR Therapy
(2018)
Patent
Engineering Specificity and Function of Therapeutic Regulatory T Cells
(2017)
Journal Article
Downloadable Citations
About Edinburgh Napier Research Repository
Administrator e-mail: repository@napier.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search